IL41476A - Picolinic acid derivatives,their manufacture and pharmaceutical compositions containing them - Google Patents

Picolinic acid derivatives,their manufacture and pharmaceutical compositions containing them

Info

Publication number
IL41476A
IL41476A IL41476A IL4147673A IL41476A IL 41476 A IL41476 A IL 41476A IL 41476 A IL41476 A IL 41476A IL 4147673 A IL4147673 A IL 4147673A IL 41476 A IL41476 A IL 41476A
Authority
IL
Israel
Prior art keywords
pyridine
butyl
compound
methoxy
amino
Prior art date
Application number
IL41476A
Other versions
IL41476A0 (en
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH230172A external-priority patent/CH570376A5/xx
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of IL41476A0 publication Critical patent/IL41476A0/en
Publication of IL41476A publication Critical patent/IL41476A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (1)

1. WHAT WE CLAIM IS: 1. A pyridine compound of the formula I in which alk is an alkyl group having 4 to 6 carbon atoms, stands for a hydroxy, lower alkoxy, cyclo-lower alkoxy or amino group, R^ and R^, independently of one another stand' for lower alkoxy, hydroxy, amino, mono- or di-lower alkyl-amino or lower alkyleneamino or halogen and one of the symbols and R^ may also represent a hydrogen atom. 2V; A compound of the formula 0 in which R^ stands for a free hydroxyl group, a lower alkoxy group or the amino group, R^ and R^, independently of one another are each lower alkoxy, halogen or hydroxyl and one of the radicals -j and R^ can also be hydrogen, and alk is an alkyl group with 4 or 5 carbon atoms. 3. A compound of the formula 41 76-2 in which one of the symbols and R^ stands for lower alkoxy and the other for hydrogen or lower alkoxy and alk is an alkyl group with 4 or 5 carbon atoms . 4. A comp in which R^ stands for hydroxy, methoxy, ethoxy or free amino, R^ and R^, independently from one another, stand for chlorine, free hydroxyl, methoxy or ethoxy and one of the radicals R^ and R^ can also be hydrogen, and alk is an alkyl group with 4 or 5 carbon atoms. 5. A compound of the formula a in which R^ and R^, independently of one another, stand for methoxy or ethoxy and one of the symbols R-j and R^ may also stand for h dro en and alk n an al l r h r 41476-2 -carboxy-4-methoxy-5-n-butyl-pyridine . -carboxy-4 , 6-dichloro-5-n-butyl-pyridine . -carboxy-4-methoxy-5-n-butyl-6-chloro-pyridine . -carboxy-4-n-propoxy-5-n-buyl-pyridine . -carboxy^4-ethoxy-5-n-butyl-pyridine . -methoxycarbonyl-5-n-butyl-6-methoxy-pyridine . -carboxy-5-n-butyl-6-methoxy-pyridine . -methoxycarbonyl-4-chlord*-5-n-butyl-6-amino-pyridi e -methoxycarbonyl-5-n-butyl-6-amino-pyridine. 1 "' -meth0xycarbonyl-4-methoxy-5-n-butyl-pyridine . -carbamoyl-4-methoxy-5-n-butyl-pyridine. -carboxy-4-methoxy-5-isoamyl-pyridine. -carboxy-4-methoxy-5-n-amyl-pyridine . -methoxycarbonyl-4-piperidino-5-n-butyl-pyridine .. 41476-2- 20. 2-methoxycarbonyl-4-piperidino-5-n-butyl-6-chloro-pyridine . 21. 2-carboxy-4-chloro-5-n-bucyl-6-meChoxy-pyridine. 22. 2-carboxy-4-methoxy-5-n-butyl-6-piperidino-pyridine . 23. 2-carboxy-4,6-dimethoxy-5-n-butyl-pyridine . 24. 2-methoxycarbonyl-4-chloro-5-n-butyl-6-hydroxy-pyridine. 25. A salt of a compound as claimed in any one of claims 1 to 24. 26. An acid addition salt of a compound as claimed in any one of claims 1 to 24. 27. A therapeutically acceptable acid addition salt of a. compound as claimed in any one of claims 1 to 24. 28. A salt with a base of an acid as claimed in any one of claims 1 to 10, 12, 17, 18 and 21 to 23. 29. A therapeutically acceptable salt with :a base of an acid as claimed in any one of claims 1 to 10, 12, 17, 18 and 21 to 23. 30. A therapeutically acceptable metal salt of an acid as claimed in any one of claims 1 to 10, 12, 17, 18 and 21 to 23. 31. A pharmaceutical composition containing a compound as claimed in any one of claims 1 to 24, 27, 29 and 30 in admixture or conjunction with a pharmaceutical excipient. 32. A pharmaceutical composition containing an anti-hyper-tensively acitve aminoacid and a compound as claimed in any one of claims 1 to 24, 27, 29 and 30 in admixture or conjunction with a pharmaceutical excipient. 33. A pharmaceutical composition according to claim 32, containing a compound of the type of a-methyldopa as the anti-hypertensively active aminoacid. Λ 34. A pharmaceutical composition according to claim 33, containing, as the compound of the type of a-methyldopa, an α-amino-a-methyl-fl-hydroxyphenyl-propionic acid, one of its therapeutically acceptable salts or one of its esters. 35. A pharmaceutical composition according to claim 33, containing, as the compound of the type of α-methyldopa, a-amino-a-methyl-fi- (4-hydroxyphenyl) -propionic acid, a-amino-a-methyl-fl- (3 ,4-dihydroxyphenyl) -propionic acid, a therapeutically acceptable salt thereof or a lower alkyl ester thereof, and a compound as claimed in any one of claims 1 to 24, 27 29 and 30. 36. A pharmaceutical composition according to claim 33 containing, a) a-amino-a-methyl-fl- (3, -dihydroxyphenyl) -propionic acid or an alkali metal salt thereof, and b) 2-carbbxy-4-methoxy-5-n-butyl-pyridine or a non-toxic salt thereof. 37. A pharmaceutical composition according to any one of claims 32 to 36, containing 100-200 mg of a-amino-a-methyl-fl-(3, -dihydroxyphenyl) -propionic acid and 50-200 mg of the calcium salt of 2-carboxy-4-methoxy-5-n-butyl-pyridine . ' ;,< 38. A pharmaceutical composition according to any one of claims 32 to 27, containing 150-200 mg of a-amino- -methyl-fi-(3 ,4-dihydroxyphenyl) -propionic acid and 100-200 mg of the calcium salt of 2-carboxy-4-methoxy-5-n-butyl-pyridine . 39. A process for the manufacture of a pyridine compound as claimed in claim 1 or of a salt thereof, characterised in that a compound of the formula wherein alk, R.-, an< ^ave meanings given in claim 1 hydrate thereof, is oxidised and, if desired, in 41476-compounds obtained substituents are introduced, modified or split off within the framework of the definition of the final substances, or compounds obtained are converted into other final substances, and/or racemates obtained are split into the optical antipodes, and/or free compounds obtained are converted into their salts or salts obtained are converted into free compounds or other salts. AO, A process according to claim 39, characterised in that in compounds obtained esterified carboxyl groups, carbamoyl groups or thiocarbamoyl groups are hydrolysed to free carboxyl groups. . :. , 41. Process according to claim 39 or 40, characterised in that in compounds obtained free or esterified carboxyl groups are converted into carbamoyl groups. 42. A process according of any one of claims 3 ;to 41 , characterised in that in compounds obtained free carboxyl groups are esterified. 43. Process according to any one of claims 39 to 42, characterised in that in compounds obtained hydroxyl groups are etherified . 44. Process according to any one of claims 39 to 43, characterised in that in compounds obtained alkoxy groups are converted into hydroxyl groups. . 41476-2 45. Process according to any one of claims 39 to 44, characterised in that in compounds obtained which contain a mono- or di-lower alk lamino group or a lower alkylenamino group, this group is oxidised to a free amino group. 46. A process according to any one of claims 39 to 45, characterised in that in compounds obtained halogen is splitt off by reduction. 47. A process according to any one of claims 39 -to :45, ! characterised in that in compounds obtained halogen is converted into an amino group. 48. A process according to any one of claims 39 to 45 , characterised in that in compounds obtained halogen is ,converted into hydroxyl or alkoxy. 49. A process according to any one of claims 39 to 48, characterised in that in compounds obtained amino groups which posses at least one hydrogen atom are substituted. 50. A process according to any one of claims 39 to 49, characterised in that a compound obtainable as an intermediate product at any stage of the process is used as the starting compound and the missing process steps are carried out, or the process is stopped at any stage or a starting substance is formed under the reaction conditions, or a reactant is employed, if appropriate, in the form of one of its deri-, vatives. 41476-2 51. Process according to claim 50, characterised in that a compound of the formula wherein R^, R4 and alk have the meanings given in claim 1 and X' is methyl, hydroxymethyl, halogenomethyl, vinyl or styryl is oxidised. ' ί =· · .
IL41476A 1972-02-17 1973-02-06 Picolinic acid derivatives,their manufacture and pharmaceutical compositions containing them IL41476A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH230172A CH570376A5 (en) 1972-02-17 1972-02-17
CH1354372 1972-09-15
CH1872972 1972-12-22

Publications (2)

Publication Number Publication Date
IL41476A0 IL41476A0 (en) 1973-04-30
IL41476A true IL41476A (en) 1976-06-30

Family

ID=27173606

Family Applications (1)

Application Number Title Priority Date Filing Date
IL41476A IL41476A (en) 1972-02-17 1973-02-06 Picolinic acid derivatives,their manufacture and pharmaceutical compositions containing them

Country Status (9)

Country Link
AR (3) AR204708A1 (en)
DD (1) DD104977A5 (en)
EG (1) EG10917A (en)
ES (1) ES411657A1 (en)
HU (1) HU171241B (en)
IE (1) IE37260B1 (en)
IL (1) IL41476A (en)
PH (1) PH10009A (en)
RO (1) RO62813A (en)

Also Published As

Publication number Publication date
RO62813A (en) 1977-11-15
ES411657A1 (en) 1977-03-01
IE37260L (en) 1973-08-17
PH10009A (en) 1976-07-13
HU171241B (en) 1977-12-28
IE37260B1 (en) 1977-06-08
DD104977A5 (en) 1974-04-05
AR200160A1 (en) 1974-10-24
EG10917A (en) 1976-08-31
AR204708A1 (en) 1976-02-27
IL41476A0 (en) 1973-04-30
AR202045A1 (en) 1975-05-09

Similar Documents

Publication Publication Date Title
GEP19960467B (en) Method of producing derivatives of quinoline or their pharmaceutically acceptable esters or acid-additive salts
US3369025A (en) 3-pyridylmethyl phenoxy (phenylthio and anilino) alkanoates
IE44942L (en) Piperazine and piperidine derivatives
IE41528L (en) Furfuryl-benzomorphane derivatives.
IE39602L (en) Alkoxyalkyl-1,4-dihydropyridines
IL41476A (en) Picolinic acid derivatives,their manufacture and pharmaceutical compositions containing them
HUT67137A (en) Substituted mendelic acid derivatives. process for their production and pharmaceutical compositions comprising them
AU1572188A (en) Process for the preparation of quinoline carboxylic acids
IE892520L (en) An improved process for the preparation of¹n,n&#39;-bis-(alkoxyalkyl)-pyridine-2,4-dicarboxamides
Van Kerk et al. Investigations on organo‐tin compounds. XI. The alkaline hydrolysis of organo‐tin esters and nitriles
GB1432503A (en) Cycloalkylalkylesters and process for their preparation
LT3394B (en) Inclusion complexes of n-ethoxycarbonyl-3-morpholinosydnonimine or salts formed with cyclodextrine-derivatives, preparation thereof and pharmaceutical compositions containing the same a
US3787423A (en) Beta-picolyloxy ester of(3-trifluoromethylphenoxy)(4-chlorophenyl)acetic acid and derivatives
IE32230B1 (en) Process for the preparation of 7-aminocephalosporanic acid and its derivatives
US3563998A (en) 2 - (4 - (2&#39;,6&#39; - diphenyl - 4 - pyridyl)phenoxy)-and 2 - (4 - (4&#39;,6&#39; - diphenyl - 2 -pyridyl)phenoxy) lower aliphatic monocarbocylic acids and esters
US3703519A (en) Piperazinium mono(acetylsalicylate)
JPS60255798A (en) Preparation of phosphatidylcholine derivative
JP4392922B2 (en) Preparation of alkali metal salt of α-hydroxycarboxylic acid titanium
IL38650A (en) N-acyl-(piperazinoalkyl)-pyrazoles and their preparation
GB1243038A (en) New cyclohexenylacetic acid derivatives and process for preparing them
IL42250A (en) 6alpha-methylprednisolone-21-metasulphobenzoate preparation process and pharmaceutical compositions
GB1410275A (en) Phenoxycarboxylic acid derivatives their preparation and compositions containing them
JPS5993049A (en) 2-(2,6-dimethyl-3,5-diethoxycarbonyl-1,4-dihydropyridine-4- carboxamide)gultaric acid,disodium salt and manufacture
US1956889A (en) Salts of dialkylaminoarylphosphinous acids and process of making them
KR900006030B1 (en) Process for preparing L-ascorbyl-2-polyphosphate ester